找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: New Therapies in Advanced Cutaneous Malignancies; Piotr Rutkowski,Mario Mandalà Book 2021 The Editor(s) (if applicable) and The Author(s),

[復(fù)制鏈接]
樓主: Mosquito
11#
發(fā)表于 2025-3-23 11:10:46 | 只看該作者
12#
發(fā)表于 2025-3-23 14:31:09 | 只看該作者
13#
發(fā)表于 2025-3-23 22:05:05 | 只看該作者
Dabrafenib and Trametinibta confirming significant improvement in overall survival and progression-free survival over vemurafenib therapy or dabrafenib alone. The next indication in melanoma for the combination of these drugs is adjuvant therapy, which was approved on the basis of long-term outcomes of study resulting in a
14#
發(fā)表于 2025-3-23 22:42:31 | 只看該作者
15#
發(fā)表于 2025-3-24 05:57:51 | 只看該作者
16#
發(fā)表于 2025-3-24 09:26:20 | 只看該作者
Vismodegib and differentiation. Hh pathway is inactive in most normal adult tissues, and this pathway reactivation is involved in the pathogenesis of several malignancies like basal cell carcinoma. Vismodegib has been approved for locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
17#
發(fā)表于 2025-3-24 12:34:50 | 只看該作者
18#
發(fā)表于 2025-3-24 17:57:34 | 只看該作者
19#
發(fā)表于 2025-3-24 21:10:37 | 只看該作者
Nivolumab in Melanoma: An Overview of Medical Literature and Future Perspectivesand adjuvant treatment of melanoma. The first checkpoint inhibitor to be approved by FDA and EMA for treatment of melanoma was ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, based on proven benefit in terms of overall survival and recurrence-free survival in advanced and ear
20#
發(fā)表于 2025-3-25 00:41:36 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 03:09
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
砚山县| 湖南省| 即墨市| 黄大仙区| 镇远县| 平舆县| 渝中区| 香格里拉县| 肥城市| 荆门市| 白水县| 成安县| 嘉祥县| 上蔡县| 承德县| 台中县| 类乌齐县| 芒康县| 德昌县| 邵东县| 讷河市| 务川| 冷水江市| 遂溪县| 临沧市| 安庆市| 洛浦县| 宝丰县| 林西县| 乐至县| 芜湖县| 融水| 永丰县| 牟定县| 南丰县| 乌恰县| 原平市| 安顺市| 杭锦旗| 天镇县| 福建省|